Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting

Effect of the CYP2C8 Genotype on the Pharmacokinetics and Pharmacodynamics of Repaglinide

(2011) D. Tomalik-Scharte et al.   DRUG METABOLISM AND DISPOSITION

Severe sulfonylurea-induced hypoglycemia: a problem of uncritical prescription and deficiencies of diabetes care in geriatric patients

(2010) Andreas Holstein et al.   Expert Opinion On Drug Safety

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers

(2010) H. Shao et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

(2009) Bo Tan et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Presence ofCYP2C9*3allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas

(2009) Georgia Ragia et al.   PHARMACOGENOMICS

Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide

(2008) H Xu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Need for reassessment of reportedCYP2C19allele frequencies in various populations in view ofCYP2C19*17discovery: the case of Greece

(2008) Georgia Ragia et al.   PHARMACOGENOMICS